Skip to Main Content

As more emphasis is placed on the value of prescription medicines, a new study found cost-effectiveness analyses were unavailable for many of the medicines that accounted for a large share of Medicare Part D spending in 2016. And more than half of the analyses that were conducted failed to meet minimum standards.

Specifically, cost-effectiveness was not studied for 115 of the 250 drugs for which Part D spending was greatest in 2016, the last year for which complete data was available when the study began. Those medicines accounted for 33% of the $146.1 billion in total Part D spending that year, according to the study published in JAMA Network Open.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment